Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19
Karimpour-Razkenari et al.,
Evaluating the Effects of Clinical Characteristics and Therapeutic Regimens on Mortality in Hospitalized..,
Journal of Pharmaceutical Care, doi:10.18502/jpc.v10i3.10790
Retrospective 478 moderate to severe hospitalized patients in Iran, showing higher mortality with aspirin treatment. Authors note
confounding by indication for aspirin treatment.
This study is excluded in the after exclusion results of meta
analysis:
substantial unadjusted
confounding by indication likely.
risk of death, 123.2% higher, RR 2.23, p = 0.008, treatment 39 of 90 (43.3%), control 64 of 363 (17.6%), adjusted per study, inverted to make RR<1 favor treatment, odds ratio converted to relative risk, multivariable.
|
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
|
Karimpour-Razkenari et al., 3 Oct 2022, retrospective, Iran, peer-reviewed, median age 58.5, 9 authors, study period 23 February, 2020 - 23 May, 2020.
Contact:
ghazaeianm@gmail.com.
Abstract: 2022
Evaluating the Effects of Clinical Characteristics and Therapeutic
Regimens on Mortality in Hospitalized Patients with Severe COVID-19
Elahe Karimpour-Razkenari1, Javad Boskabadi1, Monireh Ghazaeian2*, Hamidreza Samaee1,
Hanieh Azizi1, Fatemeh Esfandiari3, Seyed Abdollah Mousavi4, Sahar Fallah5, Sekineh Talebi6
Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
1
Pharmaceutical Sciences Research Center, Department of Clinical Pharmacy, Faculty of Pharmacy, Mazandaran University of Medical Sciences,
Sari, Iran.
2
School of Medicine, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
3
Department of Pediatric Surgery, Pediatric Infectious Diseases Research Center, Mazandaran University of Medical Sciences, Sari, Iran.
4
Department of Biostatistic, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
5
Department of Nursing, Ibne Sina Medical and Educational Center, Mazandaran University of Medical Sciences, Sari, Mazandaran, Iran.
6
Received: 2022-03-29, Revised: 2022-06-10, Accepted: 2022-06-11, Published: 2022-09-30
ARTICLE INFO
ABSTRACT
Article type:
Original article
Background: The coronavirus disease 2019 (COVID-19) is highly contagious and has turned
into a global health problem. In this study, we investigated the role of clinical and laboratory
characteristics along with administered therapeutic agents in patients with COVID-19, and
identified some effective factors on the mortality of these individuals.
Keywords:
COVID-19;
Mortality;
Epidemiology
Methods: In this retrospective study, we evaluated the data from all the hospitalized patients who
had been diagnosed with COVID-19 between February 23 and May 23, 2020. The data were
obtained from medical records. Additionally, a checklist was used to record demographic, clinical,
laboratory, imaging, and treatment data for each patient.
Results: Totally, 478 patients were involved in this study, and their median age was 58.5 years. Of
these, 53.3% patients were male. The most common pre-existing underlying disease was hypertension
(37.9%), and the mortality group had significantly more comorbidities (85.4%). Higher neutrophil
lymphocyte ratio (NLR), lymphopenia, and reduced hemoglobin were more frequent in the mortality
group (p < 0.001). Similarly, the need to be admitted to the intensive care unit was significantly
greater in the mortality group (p<0.001). The most frequently administered therapeutic regimens
included hydroxychloroquine and lopinavir/ritonavir, which did not have any correlation with survival
outcome.
Conclusion: Older age, opioid addiction, cardiovascular disease, kidney disease, baseline NLR and
hemoglobin, and ICU admission were independently associated with COVID-19 mortality. On the other
hand, hydroxychloroquine and lopinavir/ritonavir indicated no beneficial effects on patients’ outcome.
J Pharm Care 2022; 10(3): 103-114.
Please cite this paper as:
Karimpour-Rrazkenari E, Boskabadi J, Ghazaeian M, Samaee H, Azizi H, Esfandiari F, et al. Evaluating the Effects of Clinical Characteristics
and Therapeutic Regimens on Mortality in Hospitalized Patients with Severe COVID-19. J Pharm Care 2022; 10(3): 103-114.
Late treatment
is less effective
karimpourrazkenari2
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation.
FLCCC and
WCH
provide treatment protocols.
Submit